Skip to main content
Premium Trial:

Request an Annual Quote

Aventis CropScience Renews Genomics Agreement with Lynx

Premium

H

AYWARD, Calif.--Aventis CropScience of Lyon, France, has renewed its nonexclusive access to Lynx Therapeutics' genomics discovery services, limited to the agricultural field, for an additional year. The renewal includes payment of a fee for genomics discovery services to be performed by Lynx. Aventis CropScience initially obtained access to Lynx's services in March 1999, through activation of an existing agreement by their affiliate, Aventis Pharmaceuticals. In addition, Lynx and Aventis CropScience signed a three-year research collaboration agreement last September, which provides Aventis CropScience with exclusive access to Lynx's genomics technology for the study of certain plants, development of genomic maps, and the discovery of trait-associated single-nucleotide polymorphisms for the subject plants.

Filed under

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.